ZDA
JAZZ icon

Zweig-DiMenna Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Zweig-DiMenna Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,700
Closed -$250K – 293
2014
Q2 		$250K Buy
1,700
+100
+6% +$13.9K 0.01% 221
2014
Q1 		$222K Buy
+1,600
New +$241K 0.01% 218

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Zweig-DiMenna Associates's JAZZ Position: Q3 2014 in Review

Zweig-DiMenna Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2014, closing a stake of 1,700 shares — an estimated $250K sold.

Zweig-DiMenna Associates first reported a position in JAZZ in Q1 2014 and held it in 2 quarters. The position peaked at $250K in Q2 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • Zweig-DiMenna Associates reported no remaining Jazz Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 1,700 Jazz Pharmaceuticals shares in Q3 2014, an estimated $250K.
  • Zweig-DiMenna Associates first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Zweig-DiMenna Associates's Jazz Pharmaceuticals position peaked at $250K in Q2 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2014, filed 10 Nov 2014.